Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

28 czerwca 2016 zaktualizowane przez: Bristol-Myers Squibb

A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

248

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Gauteng
      • Johannesburg, Gauteng, Afryka Południowa, 2199
        • Local Institution
    • Western Cape
      • Cape Town, Western Cape, Afryka Południowa, 7570
        • Local Institution
      • Buenos Aires, Argentyna, CP1280AEB
        • Local Institution
      • Wels, Austria, A-4600
        • Local Institution
      • Wien, Austria, 1090
        • Local Institution
      • Brussels, Belgia, 1090
        • Local Institution
      • Brussels, Belgia, 1070
        • Local Institution
      • Bruxelles, Belgia, 1200
        • Local Institution
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazylia, 90610
        • Local Institution
      • Porto Alegre, Rio Grande Do Sul, Brazylia, 90050
        • Local Institution
    • Sao Paulo
      • Jau, Sao Paulo, Brazylia, 17210
        • Local Institution
      • Aarhus C, Dania, 8000
        • Local Institution
      • St. Petersburg, Federacja Rosyjska, 191104
        • Local Institution
      • Stavropol, Federacja Rosyjska, 355047
        • Local Institution
      • Voronezh, Federacja Rosyjska, 394000
        • Local Institution
      • Brest, Francja, 29200
        • Local Institution
      • Lyon Cedex 08, Francja, 69373
        • Local Institution
      • Paris, Francja, 75010
        • Local Institution
      • Vandoeuvre Les Nancy, Francja, 54511
        • Local Institution
      • Malaga, Hiszpania, 29010
        • Local Institution
      • Valencia, Hiszpania, 46009
        • Local Institution
      • Jerusalem, Izrael, 91120
        • Local Institution
      • Tel-Aviv, Izrael, 64239
        • Local Institution
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
        • Local Institution
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Local Institution
    • New Brunswick
      • Moncton, New Brunswick, Kanada, E1C 6Z8
        • Local Institution
      • Berlin, Niemcy, D-12200
        • Local Institution
      • Heidelberg, Niemcy, 69120
        • Local Institution
      • Kiel, Niemcy, D-24105
        • Local Institution
      • Oslo, Norwegia, 0310
        • Local Institution
      • Lodz, Polska, 90553
        • Local Institution
      • Poznan, Polska, 61-866
        • Local Institution
      • Wroclaw, Polska, 51-124
        • Local Institution
      • Olomouc, Republika Czeska, 775 20
        • Local Institution
    • Arizona
      • Tucson, Arizona, Stany Zjednoczone, 85719
        • University of Arizona Cancer Center
    • California
      • Laverne, California, Stany Zjednoczone, 91750
        • Wilshire Oncology Medical Group Inc
      • Los Angeles, California, Stany Zjednoczone, 90033
        • USC/Norris Comprehensive Cancer Center
      • Los Angeles, California, Stany Zjednoczone, 90025
        • The Angeles Clinic & Research Inst.
      • San Francisco, California, Stany Zjednoczone, 94115
        • San Francisco Oncology Associates
    • Connecticut
      • To come, Connecticut, Stany Zjednoczone
        • Local Institution
    • Florida
      • Jacksonville, Florida, Stany Zjednoczone, 32207
        • Baptist Cancer Institute
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60637
        • University of Chicago
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Indiana Oncology Hematology Consultants
    • Missouri
      • Saint Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
      • St Joseph, Missouri, Stany Zjednoczone, 64507
        • St Joseph Oncology Inc
    • New York
      • New York, New York, Stany Zjednoczone, 10065
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28203
        • Carolinas Medical Center
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45219
        • The Christ Hospital Cancer Center Research
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97213
        • Providence Portland Medical Center
    • South Carolina
      • Greenville, South Carolina, Stany Zjednoczone, 29615
        • Cancer Centers of the Carolinas
    • Texas
      • Dallas, Texas, Stany Zjednoczone, 75230
        • Center For Oncology Research & Treatment, P.A.
      • Lubbock, Texas, Stany Zjednoczone, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98109
        • University of Washington Medical Center
      • Dnepropetrovsk, Ukraina, 49044
        • Local Institution
      • Genova, Włochy, 16132
        • Local Institution
      • Meldola (Fc), Włochy, 47014
        • Local Institution
      • Rimini, Włochy, 47900
        • Local Institution
      • Siena, Włochy, 53100
        • Local Institution

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria

  • Diagnosis of advanced melanoma
  • Prior treatment in a prespecified prior/parent ipilimumab study
  • Men and women 18 years of age and older

First Reinduction:

  • No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
  • Had experienced documented progressive disease after expanded clinical benefit

Extended Maintenance

  • Received ipilimumab at any dose in a parent study
  • Achieved expanded clinical benefit at the time of entry to current study

Follow-up:

  • Received ipilimumab at any dose in a closing parent study
  • Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up

Key Exclusion Criteria

  • Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
  • Primary ocular or mucosal melanoma

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Eksperymentalny: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Eksperymentalny: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Eksperymentalny: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Eksperymentalny: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Eksperymentalny: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
  • BMS-734016
  • MDX-010
Brak interwencji: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
Ramy czasowe: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related is defined as having certain, probable, possible, or missing relationship to study drug. An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Overall Survival (OS)
Ramy czasowe: From first dose of study drug in parent study to death or date of last censoring.
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death. If a patient has not died, OS was censored at the time of last contact.
From first dose of study drug in parent study to death or date of last censoring.
Percentage of Participants Surviving at 1, 1.5, and 2 Years
Ramy czasowe: From first dose of study drug in parent study to up to 2 years after reinduction
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
From first dose of study drug in parent study to up to 2 years after reinduction
Number of Participants With On-study Immune-related Adverse Events (irAEs)
Ramy czasowe: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related. These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems). Patients may have 1 or more events.
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
Progression-free Survival (PFS)
Ramy czasowe: From day of first reinduction in current study to date of progression or death, whichever occurred first.
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
From day of first reinduction in current study to date of progression or death, whichever occurred first.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 maja 2006

Zakończenie podstawowe (Rzeczywisty)

1 września 2012

Ukończenie studiów (Rzeczywisty)

1 kwietnia 2014

Daty rejestracji na studia

Pierwszy przesłany

9 września 2005

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 września 2005

Pierwszy wysłany (Oszacować)

13 września 2005

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

27 lipca 2016

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

28 czerwca 2016

Ostatnia weryfikacja

1 czerwca 2016

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj